NOMURA HOLDINGS INC-SPON ADR (NMR)

US65535H2085 - ADR

6.05  0 (0%)

After market: 6.05 0 (0%)

Fundamental Rating

3

Overall NMR gets a fundamental rating of 3 out of 10. We evaluated NMR against 213 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR is not valued too expensively and it also shows a decent growth rate.



2

1. Profitability

1.1 Basic Checks

In the past year NMR was profitable.
In the past year NMR had a positive cash flow from operations.
Each year in the past 5 years NMR has been profitable.
In multiple years NMR reported negative operating cash flow during the last 5 years.

1.2 Ratios

The Return On Assets of NMR (0.30%) is worse than 76.67% of its industry peers.
The Return On Equity of NMR (4.95%) is worse than 68.57% of its industry peers.
The Return On Invested Capital of NMR (0.34%) is worse than 81.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NMR is significantly below the industry average of 7.99%.
The last Return On Invested Capital (0.34%) for NMR is above the 3 year average (0.31%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.3%
ROE 4.95%
ROIC 0.34%
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%

1.3 Margins

With a Profit Margin value of 3.99%, NMR is not doing good in the industry: 72.86% of the companies in the same industry are doing better.
NMR's Profit Margin has declined in the last couple of years.
NMR has a worse Operating Margin (6.59%) than 80.00% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
NMR has a worse Gross Margin (37.57%) than 68.57% of its industry peers.
NMR's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.59%
PM (TTM) 3.99%
GM 37.57%
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, NMR has less shares outstanding
Compared to 5 years ago, NMR has less shares outstanding
NMR has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.29, we must say that NMR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.29, NMR is not doing good in the industry: 88.57% of the companies in the same industry are doing better.
NMR has a Debt/Equity ratio of 10.52. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 10.52, NMR is not doing good in the industry: 90.95% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 10.52
Debt/FCF N/A
Altman-Z -0.29
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.22 indicates that NMR may have some problems paying its short term obligations.
NMR's Current ratio of 0.22 is on the low side compared to the rest of the industry. NMR is outperformed by 86.19% of its industry peers.
NMR has a Quick Ratio of 0.22. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of NMR (0.22) is worse than 86.19% of its industry peers.
Industry RankSector Rank
Current Ratio 0.22
Quick Ratio 0.22

6

3. Growth

3.1 Past

NMR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.88%, which is quite impressive.
NMR shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.71% yearly.
Looking at the last year, NMR shows a very strong growth in Revenue. The Revenue has grown by 67.18%.
The Revenue has been growing by 17.77% on average over the past years. This is quite good.
EPS 1Y (TTM)76.88%
EPS 3Y2.71%
EPS 5YN/A
EPS Q2Q%669.08%
Revenue 1Y (TTM)67.18%
Revenue growth 3Y36.99%
Revenue growth 5Y17.77%
Sales Q2Q%51.91%

3.2 Future

The Earnings Per Share is expected to grow by 15.95% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.35% on average over the next years.
EPS Next Y56.69%
EPS Next 2Y27.83%
EPS Next 3Y15.95%
EPS Next 5YN/A
Revenue Next Year7.75%
Revenue Next 2Y4.05%
Revenue Next 3Y2.35%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 17.29, which indicates a rather expensive current valuation of NMR.
NMR's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 29.19. NMR is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 10.39, the valuation of NMR can be described as reasonable.
NMR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NMR is cheaper than 64.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.63. NMR is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 17.29
Fwd PE 10.39

4.2 Price Multiples

NMR's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 32.97

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NMR's earnings are expected to grow with 15.95% in the coming years.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y27.83%
EPS Next 3Y15.95%

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 2.38%, NMR has a reasonable but not impressive dividend return.
NMR's Dividend Yield is slightly below the industry average, which is at 7.39.
Compared to an average S&P500 Dividend Yield of 2.33, NMR has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.38%

5.2 History

The dividend of NMR is nicely growing with an annual growth rate of 7.29%!
NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
NMR has decreased its dividend recently.
Dividend Growth(5Y)7.29%
Div Incr Years1
Div Non Decr Years1

5.3 Sustainability

NMR pays out 36.27% of its income as dividend. This is a sustainable payout ratio.
NMR's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP36.27%
EPS Next 2Y27.83%
EPS Next 3Y15.95%

NOMURA HOLDINGS INC-SPON ADR

NYSE:NMR (7/15/2024, 7:04:01 PM)

After market: 6.05 0 (0%)

6.05

0 (0%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap17.87B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 2.38%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 17.29
Fwd PE 10.39
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.3
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.3%
ROE 4.95%
ROCE
ROIC
ROICexc
ROICexgc
OM 6.59%
PM (TTM) 3.99%
GM 37.57%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 10.52
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.22
Quick Ratio 0.22
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)76.88%
EPS 3Y2.71%
EPS 5Y
EPS Q2Q%
EPS Next Y56.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)67.18%
Revenue growth 3Y36.99%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y